Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to keep narcolepsy patients awake and steady

NCT ID NCT06505031

Completed Symptom relief Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tested an experimental drug called TAK-861 in 105 adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants took either TAK-861 or a placebo daily for 3 months. The main goal was to see if the drug helps people stay awake during the day and reduces cataplexy attacks. Researchers also checked safety and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TAK-861 (oral tablet)
What this could lead to
If successful, TAK-861 could offer a new treatment option to reduce daytime sleepiness and sudden muscle weakness attacks in people with narcolepsy type 1.
What could go wrong
This is a completed Phase 3 trial with only 105 participants, so results may not apply to everyone. The drug may cause side effects and might not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NARCOLEPSY TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NARCOLEPSY TYPE 1

Contacts and locations

Locations

  • 28003

    Barcelona, 08035, Spain

  • Takeda Site 1

    Glebe, New South Wales, Australia

  • Takeda Site 10

    Suwon, Gyeonggi-do, 16247, South Korea

  • Takeda Site 11

    Seoul, Daegu, 41931, South Korea

  • Takeda Site 12

    Seoul, 3080, South Korea

  • Takeda Site 13

    Madrid, Spain

  • Takeda Site 14

    Marseille, 13385, France

  • Takeda Site 15

    Nantes, 44093, France

  • Takeda Site 16

    Léon, Bordeaux, 33076, France

  • Takeda Site 17

    Pozzilli, 86077, Italy

  • Takeda Site 19

    Uppsala, Sweden

  • Takeda Site 2

    Alken, Belgium

  • Takeda Site 20

    Helsinki, 380, Finland

  • Takeda Site 21

    Tampere, 33520, Finland

  • Takeda Site 22

    Linz, 4020, Austria

  • Takeda Site 23

    Liège, 4000, Belgium

  • Takeda Site 24

    Leuven, 3000, Belgium

  • Takeda Site 25

    Ghent, 9000, Belgium

  • Takeda Site 26

    Guangdong, China

  • Takeda Site 27

    Zhengzhou, Henan, China

  • Takeda Site 28

    Shanghai, Shanghai Municipality, China

  • Takeda Site 3

    Erpent, 5101, Belgium

  • Takeda Site 4

    Beijing, Beijing Municipality, China

  • Takeda Site 5

    Montpellier, France

  • Takeda Site 6

    Bron, France

  • Takeda Site 7

    Bologna, 40139, Italy

  • Takeda Site 8

    Roma, Italy

  • Takeda Site 9

    Krakow, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.